Neoadjuvant systemic therapy in breast cancer;Neoadjuváns szisztémás terápia emlorákban

Orvosi Hetilap

Volumn 150, Issue 2, 2009, Pages 65-71

  Kahán, Zsuzsanna ^a,b   Nikolényi, Aliz ^a   Uhercsák, Gabriella ^a   Thurzó, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b NONE   (Hungary)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Neoadjuvant hormone therapy; Neoadjuvant systemic therapy; Predictive factors

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; ERLOTINIB; EXEMESTANE; GEFITINIB; LAPATINIB; LETROZOLE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DIAGNOSTIC IMAGING; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; POSTMENOPAUSE; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIMARY TUMOR; PROGNOSIS; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR REGRESSION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CANCER STAGING; FEMALE; LYMPHADENECTOMY; METHODOLOGY; PATHOLOGY; REVIEW; SEGMENTAL MASTECTOMY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY, SEGMENTAL; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS; RADIOTHERAPY, ADJUVANT;

EID: 60749122412     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2009.28536     Document Type: Article

References (46)

1. [1] Mauri, D., Pavlidis, N., Ioannidis, J. P. A.: Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J. Natl. Cancer Inst., 2005, 97, 188-194. (Pubitemid 40277368)
2. Guarneri, V., Frassoldati, A., Giovannelli, S. és mtsai: Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives. Cancer Lett., 2006, 248, 175-185.
3. Carey, L. A., Metzger, R., Dees, E. C. és mtsai: American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J. Natl. Cancer Inst., 2005, 97, 1137-1142.
4. Mazouni, C., Peintinger, F., Wan-Kau, S. és mtsai: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J. Clin. Oncol., 2007, 25, 2650-2655.
5. Kaufmann, M., von Minckwitz, G., Smith, R. és mtsai: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review recommendations. J. Clin. Oncol., 2003, 21, 2600-2608.
6. Kaufmann, M., Hortobagyi, G. N., Goldhirsch és mtsai: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J. Clin. Oncol., 2006, 24, 1940-1949.
7. Gralow, J. R., Burstein, H. J., Wood, W. és mtsai: Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J. Clin. Oncol., 2008, 26, 814-819.
8. Kuhl, C.: Current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Clinical applications. Radiology, 2007, 244, 356-378.
9. [9] Kuhl, C. K.: Current status of breast MR imaging. Part II. Clinical applications. Radiology, 2007, 244, 672-691. (Pubitemid 47292079)
10. Jones, R. L., Salter J., A'Hern, R. és mtsai: The prognostic signifi cance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res. Treat., 2008. Epub ahead of print.
11. Gianni, L., Zambetti, M., Clark, K. és mtsai: Gene expression profi les in paraffi n-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol., 2005, 23, 7265-7277.
12. Rouzier, R., Pusztai, L., Symmans, W. F. és mtsai: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res., 2005, 11, 5678-5685.
13. Oh, J. L., Nguyen, G., Whitman, G. J. és mtsai: Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Can cer, 2007, 110, 2420-2427.
14. Fuster, D., Duch, J., Paredes, P. és mtsai: Preoperative staging of large primary breast cancer with [18F] fl uorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J. Clin. Oncol., 2008, 26, 4746-4751.
15. [15] Von Minckwitz, G., Costa, S. D., Raab, G. és mtsai: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J. Clin. Oncol., 2001, 19, 3506-3515. (Pubitemid 32730088)
16. Steger, G. G., Galid, A., Gnant, M. és mtsai: Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: Results of ABCSG-14. J. Clin. Oncol., 2007, 25, 2012-2018.
17. Mayer, E. L., Carey, L. A., Burstein, H. J.: Clinical trial update: implications and management of residual disease after neo adjuvant therapy for breast cancer. Breast Cancer Res., 2007, 9, 110.
18. Rody, A., Karn, T., Solbach, C. és mtsai: The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast, 2007, 16, 235-240.
19. [19] Smith, I. C., Heys, S. D., Hutcheon, A. W. és mtsai: Neoadjuvant chemotherapy in breast cancer: signifi cantly enhanced response with docetaxel. J. Clin. Oncol., 2002, 20, 1456-1466. (Pubitemid 34260523)
20. Abrial, C., Mouret-Reynier, M.-A., Curé, H. és mtsai: Neoadjuvant endocrine therapy in breast cancer. Breast, 2006, 15, 9-19.
21. Ma, C. X., Ellis, M. J.: Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin. Oncol., 2006, 33, 650-656.
22. Semiglazov, V. F., Semiglazov, V. V., Dashyan, G. A. és mtsai: Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen recep torpositive breast cancer. Cancer, 2007, 110, 244-254.
23. Dowsett, M.: Preoperative models to evaluate endocrine strategies for breast cancer. Clin. Cancer Res., 2003, 9, 502S-510S.
24. Mustacchi, G., Ceccherini, R., Milani, S. és mtsai: Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann. Oncol., 2003, 14, 414-420.
25. Smith, I. E., Dowsett, M., Ebbs, S. R. és mtsai: Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrosole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol., 2005, 23, 5108-5116.
26. Howell, A., Cuzick, J., Baum, M. és mtsai: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 2005, 365, 60-62.
27. Gianni, L., Zambetti, M., Clark, K. és mtsai: Gene expression profi les in paraffi n-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol., 2005, 23, 7265-7277.
28. Buzdar, A. U., Ibrahim, N. K., Francis, D. és mtsai: Signifi cally higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor 2-positive operable breast cancer. J. Clin. Oncol., 2005, 23, 3656-3659.
29. Mehta, R. S., Schubbert, T., Kong, K.: Trastuzumab in infl ammatory breast cancer. Ann. Oncol., 2008, 19, 1815-1817.
30. Colleoni, M., Zarich, D., Gelber, R. D. és mtsai: Preoperative systemic treatment: prediction of responsiveness. Breast, 2003, 12, 538-542.
31. Colleoni, M., Viale, G., Zahrieh, D. és mtsai: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin. Cancer Res., 2004, 10, 6622-6628.
32. Wenzel, C., Bartsch, R., Hussian, D. és mtsai: Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res. Treat., 2007, 104, 109-114.
33. Cristofanilli, M., Gonzalez-Angulo, A., Sneige, N. és mtsai: Invasive lobular carcinoma classic type: Response to primary chemotherapy and survival outcomes. J. Clin. Oncol., 2005, 23, 41-48.
34. Byrski, T., Huzarski, T., Dent, R. és mtsai: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat., 2008; DOI: 10.1007/s10549-008- 0128-129
35. Esteva, F. J., Hortobágyi, G. N.: Prognostic molecular markers in early breast cancer. Breast Cancer Res., 2004, 6, 109-118.
36. Tordai, A., Wang, J., Andre, F. és mtsai: Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res., 2008, 10, 37-46.
37. Andre, F., Mazouni, C., Liedtke, C. és mtsai: HER2 expression and effi cacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res. Treat., 2008, 108, 183-190.
38. Loibl, S., von Minckwitz, G., Raab, G. és mtsai: Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: Results of the GEPARDUO trial. Ann. Surg. Oncol., 2006, 13, 1434-1442.
39. Peintinger, F., Symmans W. F., Gonzalez-Angulo, A. M. és mtsai: The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer, 2006, 107, 1248-1254.
40. Xing, Y., Foy, M., Cox, D. D. és mtsai: Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br. J. Surg., 2006, 93, 539-546.
41. Mamounas, E. P., Brown, A., Anderson, S. és mtsai: Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol., 2005, 23, 2694-2702.
42. Denker, C.: Pathological workup of surgical breast cancer specimens after neoadjuvant chemotherapy. Breast Care, 2006, 1, 368-373.
43. Neubauer, H., Gall, C., Vogel, U. és mtsai: Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res., 2008, 28, 1797-1804.
44. McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H. és mtsai: Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achiev a pathologic complete response to neoadjuvant chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2007, 68, 1004-1009.
45. Jeruss, J. S., Mittendorf, E. A., Tucker, S. L. és mtsai: Staging of breast cancer in the neoadjuvant setting. Cancer Res., 2008, 68, 6477-6481.
46. Chen, A. M., Meric-Bernstam, F., Hunt, K. K. és mtsai: Breast conservation after neoadjuvant chemotherapy. Cancer, 2005, 103, 689-695.